Curriculum vitae & bibliography

DAVID L. PEARLE, M.D.
DAVID L. PEARLE, M.D.

PERSONAL INFORMATION

HOME ADDRESS:
(202) 444-8833 / (877) 303-1461 Facsimile
EDUCATION

1964
M.D., Harvard Medical School, Boston, Massachusetts

TRAINING/ PROFESSIONAL POSITIONS

1968-1969
Internship in Medicine, New York Hospital Residency in Medicine, New York Hospital Commissioned Officer, Public Health Service (Military Clinical Instructor of Medicine, George Washington Cardiology Fellow, Georgetown University Hospital, Washington, DC 1970 Hemodynamics Fellow, Washington Veterans Administration Hospital Washington, DC February 1975-June 1975 Staff Cardiologist, Washington Veterans Administration July 1975-March 1983 Staff Cardiologist, Georgetown University Hospital, Washington, DC Assistant Director, Coronary Care Unit, Georgetown University Hospital, Washington, DC Co-Director, Medical Special Care Unit, Georgetown University Hospital, Washington, DC Transplant Cardiologist, Georgetown University July 1988-January 1993 Acting Chief, Division of Cardiology, Georgetown Director, Cardiac Cath Laboratory, Georgetown Director, Georgetown Heart Failure Service Director, Coronary Care Unit, Georgetown University Hospital, Washington, DC Writing Group, Joint American College of Cardiology/American Heart Association Committee for Guidelines for the Management of Patients with ST-elevation Myocardial Infarction, 2004, 2008, 2009.

APPOINTMENTS

1970 Clinical Instructor of Medicine, George Washington
University Hospital, Washington, DC
1974
Instructor of Medicine, Georgetown University Hospital, Washington, DC Assistant Professor of Medicine (Cardiology), Georgetown University Hospital, Washington, DC Pharmacology, Georgetown University Hospital, Washington, DC Associate Professor of Medicine and Pharmacology, Georgetown University Hospital, Washington, DC (Tenured) Professor of Medicine, Georgetown University Hospital, Washington, DC (Tenured) Professor of Medicine, Medstar Georgetown University Hospital, Washington, DC
CERTIFICATION
1975 American Board of Internal Medicine, Subspecialty of American Board of Internal Medicine, Subspecialty of Interventional Cardiology
LICENSURE
Special Clinical Fellowship, Washington Heart Association, Donald Zucker Visiting Professor, Cornell/New York Hospital, 1991 Vicennial Medal, Georgetown University, 1994 Washingtonian Magazine, Top Doctors, 1991-2009 America’s Top Physician, Consumers Research
PROFESSIONAL SOCIETIES
 American Heart Association, National’s Capital Affiliate, President 1984-1986  Intersociety Commission for Heart Disease Resources  Fellow, American College of Cardiology  Fellow, American Heart Association, Council on Clinical Cardiology  Medical Society of the District of Columbia  Fellow, American Federation for Clinical Research  Fellow, Society for Cardiac Angiography
HOSPITAL AND MEDICAL CENTER COMMITTEES
 Chairman, CPR Committee, 1976-1985, 1999-present  Intern Selection Committee, Department of Medicine, 1976-1984  Institutional Review Board, 1978-1982  Search Committee, Pediatrics Chair, 1988  University Fiscal Affairs Committee, 1990  Search Committee, Anesthesia Chair, 1988  Medical Center Bylaws and Governance Committee, 1990  Department of Medicine Billing Committee, 1992-1996  University Faculty Grievance Committee, 1998-2000  Chairman, CPR Committee, 1999-Present  Billing Committee, Chair, 1992 - 1994  Pharmacy and Therapeutics Committee, 1999- Present RESEARCH GRANTS AWARDED
“Chlordiazepoxide for Ventricular Arrhythmias” American Heart Association, Nation’s Capital Affiliate-1975 “Nifedipine, Angina, and Myocardial Infarction Study” Pfizer laboratories-1979-1982 $72,635 Principal Investigator: David L. Pearle, MD “Nifedipine: To Determine Efficacy in Management of Angina Pectoris” Pfizer laboratories-1979-1982 Principal Investigator: David L. Pearle, MD “Open, Multi Center Trial of Ibopamine Hydrochloride in Patients with Congestive Heart Failure: Long Term Safety” Smith, Kline, and French Laboratories- 1984-1987 $176,490 Principal Investigator: David L. Pearle, MD “Double Blind, Placebo-Controlled, Multi Center Trial of Ibopamine in Patients with Congestive Heart Failure: Invasive Evaluation of Hemodynamic Parameters and Exercise Testing” Smith, Kline, and French Laboratories- 1985-1987 $176,490 Principal Investigator: David L. Pearle, MD “Open Safety Trial of Ibopamine with Captropril and Hydralazine: Acute Hemodynamic Study with Short Term Chronic Dosing” Smith, Kline, and French Laboratories- 1985-1987 $59,700 Principal Investigator: David L. Pearle, MD 7. “An Optional, Open, Long Term Study of the Effects of Flosequinan 75, 100, or 150 mg q.d. on Safety, Tolerance, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Randomized to the BP1 919 Double Blind Study” The Boots Company, U.S.A., Inc. $25,000 Principal Investigator: David L. Pearle, MD 8. “An Optional, Open-Label, Long Term Study of the Effects of Flosequinan 100 mg Once a Day (with 150 mg/ 100 mg/ 75 mg/ 50 mg up or down titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI-934” The Boots Company, U.S.A., Inc. $48,000 Principal Investigator: David L. Pearle, MD “Modern Approach to the Treatment of Hypertension Multi-Center Study (MATH)” Pfizer, Inc. $4,000 Principal Investigator: David L. Pearle, MD 10. “An Open-Label, Compassionate-Use, Long Term Study to Evaluate the of Repeated Daily Oral Doses of Flosequinan in Patients with Congestive Heart Failure” The Boots Company, U.S.A., Inc. $ N/a Principal Investigator: David L. Pearle, MD 11. “A Multi-Center, Double Blind, Placebo-Controlled Study of the Effects of Manoplax (Flosequinan) 75 mg Twice Daily or 100 mg Once Daily on Duration of Exercise Treadmill Testing and Disease Symptoms for Up to 12 Weeks in Symptomatic Congestive Heart Failure Patients on Angiotensin Converting Enzyme Inhibitors (ACEIs) The Boots Company, U.S.A., Inc. Principal Investigator: David L. Pearle, MD 12. "An Invasive Hemodynamic Study of the Effects, Safety, and Tolerability of 75 mg Twice Daily, 100 mg Once Daily, or 150 mg Once Daily Manoplax (Flosequinan) in New York Heart Association Class III or IV Congestive Heart Failure Patients Uncontrolled by Angiotensin Converting Enzyme Inhibitors (ACEIs) and Diuretics” The Boots Company, U.S.A., Inc. $420,000 Principal Investigator: David L. Pearle, MD 13. “A Double Blind, Placebo-Controlled, Parallel Group, Invasive Hemodynamic Study with Manoplax (Flosequinan) 75 mg Twice Daily, or 150 mg Once Daily for Two Weeks in New York Heart Association Class III and IV Congestive Heart Failure Patients Symptomatic on Angiotensin Converting Enzyme Inhibitors, BPI 993” The Boots Company, U.S.A., Inc. $420,700 Principal Investigator: David L. Pearle, MD 14. “An Open-Label, Long Term Study of the Effects of Manoplax (Flosequinan) 50 mg b.i.d. (with 75 mg b.i.d. upward titration or 25 mg b.i.d. downward titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI 993” $89, 800 Principal Investigator: David L. Pearle, MD 15. “U.S. Thrombolysis Registry” Medical Research International $ N/a Principal Investigator: David L. Pearle, MD 16. “Effects of Aminodipine on Exercise Tolerance and Safety in Patients with Chronic, Symptomatic (New York Heart Association Class II-IV) Heart Failure Receiving a Combination of Angiotensin Converting Enzyme Inhibitors, Digoxin, and Diuretics” Pfizer Laboratories Funded at $59,368 Current available $11,887 (funds stilled owed) Principal Investigator: David L. Pearle, MD 17. “Long Term Double Blind Evaluation of the Safety of Amlodopine in Patients with Heart Failure (175E)” Pfizer Laboratories Funded at $5,00 Current available- $4,832 Principal Investigator: David L. Pearle, MD 18. “A Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo in the Treatment of Patients with Congestive Heart Failure, New York Heart Association Class III-IV (221)” Smith, Kline, and Beecham Funded at $24,855 (Projected-$72,000) Current available $2,622 Principal Investigator: David L. Pearle, MD 19. “A Six Month Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo in the Treatment of Patients with Congestive Heart Failure, New York Heart Association Class III-IV (239)” Smith, Kline, and Beecham 1992 Funded at $5,145 (Projected-0) Current available $9,606 Principal Investigator: David L. Pearle, MD 20. “A Two Year, Open Label Multi Center, Safety Study of Twice Daily Oral Carvedilol in Patients with New York Heart Association Class I-IV Congestive Heart Failure (Extension)” Sponsor: Smith Kline and Beecham Total Grant Amount: $22,760 Amount Funded as of June 1995: $8,535 (Funds due) Status: Active Principal Investigator: David L. Pearle, MD 21. Achieve Congestive Heart Failure Investigation and Economic Variable Evaluation with Sponsor: Park Davis Total Grant Amount: $235/pt. Amount Funded as of June 1995: $1,250 Status: Active Principal Investigator: David L. Pearle, MD 22. A Multi Center Double Blind Randomized Parallel Design, Pilot Study to Evaluate the Safety and Tolerability of Losartan Administered in Addition to Enalapril in Patients with Heart Failure Treated Previously with ACE Inhibitors Sponsor: Merck and Co. Total Grant Amount: $45,000 Amount Funded as of June 1995:0 Status: Active Principal Investigator: David L. Pearle, MD 23. An Open Label Evaluation of Carvedilol in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-IV Sponsor: Smith Kline and Beecham Total Grant Amount: $500/pt. Amount Funded as of June 1995: 0 Status: Active Principal Investigator: David L. Pearle, MD 24. A Six-Month Double Blind, Multi Center Evaluation of Oral Carvedilol b.i.d. Compared with Placebo in Patients with New York Heart Association Class III-V Sponsor: Smith Kline and Beecham Total Grant Amount: $82,850 Amount Funded as of June 1995: $5,145 Status: Closed Principal Investigator: David L. Pearle, MD 25. A 12-Month Double Blind, Multi Center Comparison of Oral Carvedilol b.i.d. with Mild Congestive Heart Failure New York Heart Association Class II Sponsor: Smith Kline and Beecham Total Grant Amount: $53,795. Amount Funded as of June 1995: $9,606 Status: Closed Principal Investigator: David L. Pearle, MD 26. BEST Beta-Blocker Evaluation of Survival Trial: Bucindolol Sponsor: National Heart, Lung, and Blood Institute, Va. Coop. Total Grant Amount: $120,000 Amount Funded as of June 1995: 0 Status: Active Principal Investigator: David L. Pearle, MD 27. PRAISE II Prospective Randomized Amlodipine Survival Evaluation Sponsor: Pfizer, Inc. Total Grant Amount: to be negotiated Amount Funded as of June 1995: 0 Status: Active Principal Investigator: David L. Pearle, MD 28. VEST Vesnarinone Trial Sponsor: Otsuka Pharmaceuticals. Total Grant Amount: $78,750 Amount Funded as of June 1995: 0 Status: Active Principal Investigator: David L. Pearle, MD 29. The Effect of RO-40 on Exercise Treadmill Test Duration and Al Cause Mortality in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-V Treated for Approximately 3-Years Sponsor: Hoffman LaRoche Total Grant Amount: $128,292 Amount Funded as of April 1995: 0 Status: Closed Principal Investigator: David L. Pearle, MD
Abstracts
Pearle, D.L., Corr, P.B., and R.A Gillis. Influences of site of cardiovascular changes
induced by coronary ligation. Federal Process 33:162, 1974
Pearle, D.L., and R.A Gillis. Effects of digitalis on the response of ventricular
pacemakers to sympathetic nerve stimulation. Am J Cardiology 3:162, 1974.
Pearle, D.L., T. Hoekman, K.M. Kent, and R.A Gillis. Pharmacological analysis of a cardiac
sympathetic neural response resistant to beta-adrenergic blockage. Circulation 50: 111-37,
Supplement III, 1974.
Corr, P.B., D.L., Pearle, and R.A Gillis. Occlusion site as a determinant of the deleterious
effects of atropine in experimental myocardial infarction. Am J Cardiology 35:129, 1975.
Pearle, D.L., Williford, and R.A Gillis. Comparison of practolol and propranolol on coronary
occlusion-induced ventricular fibrillation. Am J Cardiology 41:399, 1978.
Chizner, M.D., D.L., Pearle, and A.C. deLeon Jr. Natural history of aortic stenosis in adults.
Chest 74:3322, 1978.
Pearle, D.L., J. Dias Souza, and R.A Gillis. Comparative vagolytic effects of procainamine
and n-acetylprocainamide in the dog. Clinical Research 27:139 A, 1979.
Alexander, G.J., J. Dias Souza, S.A. Segal, D.L., Pearle and R.A Gillis. Experimental
coronary artery spasm: Prevention by nisoldipine and nifedipine by not by verapamil.
Clinical Research, April 1983.
Muller, J., J. Morrison, P. Stone, R. Rude, B. Rosner, R. Roberts, D.L., Pearle, Z. Turi, J.
Schneider, D. Serfas, C. Hennekens, E. Braunwald. Nifedipine therapy for threatened and
acute myocardial infarction: A randomized double blind comparison. Circulation 68:111-
120, 1983.
Muller, J., Z. Turi, D.L., Pearle, J. Schneider, D. Serfas, J. Morrison, P. Stone, R. Rude, B. Rosner, E. Scheiner, R. Roberts, B. Sovel, C. Hennekens, E. Braunwald. Nifedipine vs. conventional therapy for unstable angina pectoris: A randomized double blind comparison. JACC 3: 551, 1984. Gatti, P.J., J. Dias Souza, J.A. Quest, P. Hamosh, D.L., Pearle, R.A Gillis. Ventricular tachyarrhythmias induced by exciting cell bodies in the area postrema of the cat. Clinical Research 32:167A, 1984. Satler, L.F., D.L., Pearle, A.A. Del Negro, K.M. Kent, S. Levine, C.E. Rackley. Reason for low hospital mortality after thrombolysis. Clinical Research 32:681A, 1984. Satler, L.F., C.E. Green, D.L., Pearle, R.S. Pallas, A.A. Del Negro, K.M. Kent, R.D. Fletcher, C.E. Rackley. The importance of metabolic support of the left ventricle after coronary thrombolysis. JACC 5:413, 1985. Krucoff, M.W., C.E. Green, L.F. Satler, F.C. Miller, R.S. Pallas, D.L., Pearle, K.M. Kent, R.D. Fletcher, C.E. Rackley. ST segment monitoring as a predictor of thrombolysis in acute myocardial infarction. JACC 5:522, 1985. Pallas, R.S., L.F. Satler, D.L., Pearle, K.M. Kent, A.A. Del Negro, C.E. Green, C.E. Rackley. Clinical course of patients undergoing emergency angiography during acute myocardial infarction. Clinical Research 32:831A, 1984. Pearle, D.L., L.F. Satler, K.M. Kent, A.A. Del Negro, N.M. Katz, R.B. Wallace, C.E. Rackley. The financial costs of intra coronary thrombolysis. Clinical Research 32:83A, 1984. Satler, L.F., N.M. Katz, K.M. Kent, D.L., Pearle, A.A. Del Negro, C.E. Rackley, R.B. Wallace. Short term mortality for coronary revascularization in the high-risk patient. Clinical Research 32:832A, 1984. Krucoff, M.W., C.E. Green, D.L., Pearle, F.C. Miller, R.S. Pallas, A.A. Del Negro, K.M. Kent, R.D. Fletcher, C.E. Rackley. Successful thrombolysis predicted by ST segment monitoring. Clinical Research 32:830A, 1984. Krucoff, M.W., C.E. Green, L.F. Satler, F.M. Miller, R.S. Pallas, D.L., Pearle, R.D. Fletcher, C.E. Rackley. The use of Holter monitoring to identify subtotal coronary occlusions. Clinical Research 32:675A, 1984. Satler, L.F., C.E. Green, D.L., Pearle, S. Levine, A.A. Del Negro, K.M. Kent, C.E. Rackley. The effects of glucose-insulin-potassium on left ventricle function after coronary thrombolysis. Clinical Research 32:681A, 1984. Satler, L.F., N.M. McNamara, R.S. Pallas, K.M. Kent, D.L., Pearle, C.E. Green, A.A. Del Negro, C.E. Rackley. Intravenous streptokinase for acute myocardial infarction during emergency ambulance transfer. Clinical Research 32:682A, 1984. Pallas, R.S., C.E. Green, L.F. Satler, D.L., Pearle, A.A. Del Negro, K.M. Kent, S. Levine, C.E. Rackley. Coronary collateral incidence and its association with multi vessel disease during acute myocardial infarction. Clinical Research 32:679A, 1984. Satler, L.F., C.E. Green, D.L., Pearle, S. Levine, A.A. Del Negro, K.M. Kent, C.E. Rackley. The beneficial effects of glucose-insulin-potassium therapy during acute thrombolysis. Circulation 70:11-153, 1984. Satler, L.F., W.J. Rogers, K.M. Kent, L.M. Fox, H. A. Goldstein, R.S. Pallas, A.A. Del Negro, D.L., Pearle, C.E. Rackley. Demonstration of salvaged myocardium after successful coronary reperfusion. Clinical Research 33:747A, 1985. Fletcher, A.M., L.F. Satler, R.S. Pallas, S.W. Ahemed, K.M. Kent, D.L., Pearle, C.E. Rackley. Therapy and cost in patients over 65 years of age hospitalized for acute myocardial infarction. Clinical Research 33:740A, 1985. Satler, L.F., R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, N.M. Katz, R. B. Wallace, C.E. Rackley. Frequency of coronary angioplasty and coronary bypass after thrombolytic therapy. Clinical Research 33:224A, 1985. McNamara, N.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, C.E. Rackley. Bleeding complications of thrombolytic therapy. Clinical Research 33:211A, 1985. Satler, L.F., C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, C.E. Rackley, K.M. Kent. Demonstration of salvaged myocardium after fibrinolytic therapy with coronary angioplasty. Clinical Research 33:224A, 1985. Pallas, R.S., D.L., Pearle, L.F. Satler, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. Angiographic characteristics of stenosis in the infarct-related vessel after streptokinase. Clinical Research 33:224A, 1985. Satler, L.F., C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, C.E. Rackley, K.M. Kent. Ischemia during angioplasty after streptokinase: A marker of salvaged myocardium. Clinical Research 33:747A, 1985. Lavelle, J.P., M.L. Leitschuh, L.F. Satler, R.S. Pallas, C.E. Green, A.A. Del Negro, D.L., Pearle, C.E. Rackley, K.M. Kent. Short and long term follow-up for coronary angioplasty in acute myocardial infarction. Clinical Research 33:744A, 1985. McNamara, N.M., L.F. Satler, S. W. Ahemed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M. Kent, C.E. Rackley. Hemorrhagic problems associated with thrombolytic therapy for acute myocardial infarction. Clinical Research 33:745A, 1985. Satler, L.F., R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, N.M. Katz, R.B. Wallace, C.E. Rackley. Hospital course after streptokinase: Frequency of coronary angioplasty and coronary bypass. Clinical Research 33:747A, 1985. Pearle, D.L., R.S. Pallas, L.F. Satler, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. The incidence of normal or near-normal infarct-related vessels after streptokinase for myocardial infarction. Clinical Research 33:173A, 1986. Fletcher, A.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, C.E. Rackley. Final treatment after thrombolytic therapy for infarction. Clinical Research 34:169A, 1986. Lavelle, J.P., L.F. Satler, R.S. Pallas, C.E. Green, A.A. Del Negro, D.L., Pearle, C.E.
Rackley, K.M. Kent. Coronary angioplasty for acute myocardial infarction: short and long
term follow up. Clinical Research 34:172A, 1986.
Pallas, R.S., L.F. Satler, D.L., Pearle, C.E. Green, A.A. Del Negro, K.M. Kent, C.E.
Rackley. Infarct vessel residual stenosis and feasbility of coronary angioplasty after
streptokinase. Clinical Research 34:173A, 1986.
McNamara, N.M., L.F. Satler, S.W. Ahmed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M.
Kent, C.E. Rackley. Bleeding complication after streptokinase for acute myocardial
infarction. Clinical Research 34:209A, 1986.
Satler, L.F., K.M. Kent, L.M. Fox, H.A. Goldstein, W.J. Rogers, R.S. Pallas, A.A. Del Negro,
D.L., Pearle, C.E. Rackley. The effects of thrombolytic therapy on inotropic contractile
reverse. Clinical Research 34:209A, 1986.
Fletcher, A.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M.
Kent, C.E. Rackley. Hospital therapy after streptokinase infusion for infarction. Clinical
Research 34:298A, 1986.
Pallas, R.S., L.F. Satler, D.L., Pearle, C.E. Green, A.A. Del Negro, K.M. Kent, C.E.
Rackley. Feasbility for coronary angioplasty after thrombolysis. Clinical Research 34:334A,
1986.
McNamara, N.M., L.F. Satler, S.W. Ahmed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M.
Kent, C.E. Rackley. Bleeding with streptokinase: Implications for therapy. Clinical
Research 34:325A, 1986.
Packer, M., K.A. Narahara, U. Elkayam, J.M. Sullivan, D.L., Pearle, B.M. Massie, M.A.
Creager (on behalf of the Principal Investigators of the REFLECT study. Mount Sinai
School of Medicine, New York, NY). Randomized, Multi Center, double blind, placebo-
controlled study of the efficacy of flosequinan, a new, long-acting vasodilator drug in
patients with chronic heart failure. Supplement to Circulation 82:111-323, October, 1990.
Publications

Gillis, R.A., D.L., Pearle, and T. Hokeman. Failure of beta adrenergic receptor blockage to
prevent arrhythmias induced by cardiac sympathetic nerve stimulation. Science 185:70,
1974.
Pearle, D.L., and R.A. Gillis. Effects of digitalis on the response of the ventricular
pacemaker to sympathetic neural stimulation and to isoproterenol. American Journal of
Cardiology 34:704, 1974.
Gillis, R.A., D.L., Pearle, and B. Levitt. Digitalis: A neuro-excitatory drug. Circulation
52:379, 1975.
Corr, P.B., D.L., Pearle, and R.A. Gillis. Coronary occlusion site as a determinant of the
cardiac rhythm effects of atropine and vagotomy. American Heart Journal 92:741, Dec.
1976.
Corr, P.B., D.L., Pearle, J.R. Hinton, W.C. Roberts, and R.A. Gillis. Site of myocardial infarction-a determinant of the cardiovascular changes induced in the cat by coronary occlusion. Circulation Research 39:840, Dec. 1976. Gillis, R.A., P.B. Corr, D.G. Pace, D.E. Evans, J. A. DiMicco, and D.L., Pearle. Role of the nervous system in experimentally induced arrhythmias. Cardiology 61:37, 1976. DiMicco, J.A., R. Prestel, D.L., Pearle, and R.A. Gillis. Mechanism of cardiovascular changes produced in cats by activation of the central nervous system with picrotoxin. Circulation Research 41:446, Oct. 1977. Pearle, D.L., D.J. Williford, and R.A. Gillis. Superiority of protocol versus propranolol in protection against ventricular fibrillation induced by coronary occlusion. American Journal of Cardiology 42:960, 1978. Pearle, D.L. Clinical experience with nifedipine for coronary artery spasm. Medical Times 107:12, Dec. 1979. Chizner, M.D., D.L., Pearle, and A.C. deLeon, Jr. Natural history of aortic stenosis in adults. American Heart Journal 99:419-424, April, 1980. Segal, S.A., D.L., Pearle, and R.A. Gillis. Coronary spasm produced by picrotoxin in cats. European Journal of Pharmacology 76: 447-451, 1981. Pearle, D.L., J. Dias Souza, and R.A. Gillis. Comparative vagolytic effects of procainamide and n-acetylprocainamide in the dog. Journal of Cardiovascular Pharmacology, 5:450-453, 1983. Pearle, D.L. Clinical experience with nifedipine for coronary artery spasm. Resident & Staff Physician 26:4, 1979. Muller, J.E., Z.G. Turi, D.L., Pearle, J.F. Schneider, D.H. Serfas, J. Morrison, P.H. Stone, R.E. Ruide, B. Rosner, B.E. Sobel, C. Tate, E. Scheiner, R. Roberts, C.H. Hennekens, and E. Braunwald. Nifedipine and conventional therapy for unstable angina pectoris: A randomized double blind comparison. Circulation 69:728-739, 1984. Muller, J.E., J. Morrison, P.H. Stone, R.E. Rude, B. Rosner, R. Roberts, D.L., Pearle, Z.G. Turi, J.F. Schneider, D.H. Serfas, C. Tate, E. Scheiner, , B.E. Sobel, C.H. Hennekens, and E. Braunwald. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double blind, placebo-controlled comparison. Circulation 69:740-747, 1984. Satler, L.F., S. Levine, A.A. Del Negro, D.L., Pearle, K.M. Kent, and C.E. Rackley. Non-surgical coronary reperfusion in evolving myocardial infarction. Advances in Internal Medicine 30:231-242, 1984. Satler, L.F., D.L., Pearle, S. Levine, C.E. Green, A.A. Del Negro, and C.E. Rackley. Aortic dissection masquerading as acute myocardial infarction: Implication for thrombolytic therapy without cardiac catherization. American Journal of Cardiology 54:1134-1135, Nov 19984. Pearle, D.L. Nifedipine in acute myocardial infarction. American Journal of Cardiology 54:21 E. 1984. Pearle, D.L. Ischemia Heart Disease: Clinical update. Monograph. Home Study Assessment. American Academy of Family Physicians 66, 1984. Satler, L.F., D.L., Pearle, S. Levine, C.E. Green, A.A. Del Negro, K.M. Kent, and C.E. Rackley. Changing concepts and treatment of unstable myocardial ischemia. Primary Cardiology 10:88-94, 1984. Gillis, R.A., B.I. Lee, and D.L., Pearle. Practical pharmacology of anti-ischemic agents. Consultant, 25-27, 68-92, April 1985. Satler, L.F., C.E. Rackley, D.L., Pearle, R.D. Fletcher, and A.A. Del Negro. Total inhibition of a physiologic pacing system due to antipacemaker-mediated tachycardiac mode. PACE 8:806-810, 1985. Satler, L.F., K.M. Kent, C.E. Green, D.L., Pearle, R.S. Pallas, A.A. Del Negro, and C.E. Rackley. Thrombolysis in acute myocardial infarction. In Advances in Critical Care Cardiology. Philadelphia: F.A. Davis Company, 1986:39-52. Rackley, C.E., L.F. Satler, D.L., Pearle, A.A. Del Negro, R.S. Pallas, and K.M. Kent. The use of hemodynamic measurements for the management of acute myocardial infarction. . In Advances in Critical Care Cardiology. Philadelphia: F.A. Davis Company, 1986:3-15. Satler, L.F., C.E. Rackley, C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, and K.M. Kent. Ischemia during angioplasty after streptokinase: A marker of myocardial salvage. American Journal of Cardiology 56:749-752, 1985. Krucoff, M.W., C.E. Green, L.F. Satler, F.C. Miller, R.S. Pallas, K.M. Kent, A.A. Del Negro, D.L., Pearle, R.D. Fletcher, and C.E. Rackley. Noninvasive detection of coronary artery patency using continuos ST segment monitoring. American Journal of Cardiology 57:916-922, 1986. Satler, L.F., K.M. Kent, L.M. Fox, C.E. Green, W.J. Rogers, R.S. Pallas, A.A. Del Negro, D.L., Pearle, and C.E. Rackley. The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. American Heart Journal 111:821-825, 1986. Rackley, C.E., L.F. Satler, M.W. Krucoff, R.S. Pallas, D.L., Pearle, A.A. Del Negro, and K.M. Kent. Future directions for the diagnosis and treatment of acute myocardial infarction. In: R.H. Cox, ed. Acute Myocardial Infarction. New York: Praeger Publisher, Inc. in press. Pearle, D.L. and C.E. Rackley. Beta-blockers and calcium channel blocking agents in acute myocardial infarction. In Advances in Critical Care Cardiology. Philadelphia: F.A. Davis Company, 1986:29-38. Katz, N.M., T.E. Kubanick, S.W. Ahmed, C.E. Green, D.L., Pearle, L.F. Satler, C.E. Rackley, and R.B. Wallace. Determinants of cardiac failure after coronary bypass surgery within 30 days of acute myocardial infarction. Satler, L.F., C.E. Green, K.M. Kent, R.S. Pallas, D.L., Pearle, and C.E. Rackley. Metabolic support during coronary reperfusion. American Heart Journal 114:54-58, 1987. Satler, L.F., R.S. Pallas, O.B. Bond, C.E. Green, D.L., Pearle, G.L. Schaer, K.M. Kent, and C.E. Rackley. Assessment of the residual coronary arterial stenosis after thrombolytic therapy during acute myocardial infarction. American Journal of Cardiology 59:1231-1233, 1987. Satler, L.F., C.E. Green, N.M. McNamara, J.P. Lavelle, R.S. Pallas, D.L., Pearle, K.M. Kent, and C.E. Rackley. Late angiographic follow-up after successful thrombolysis and angioplasty. American Journal of Cardiology 60:210-213, 1987. Bowman, M.A., and D.L., Pearle. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education Health Professional 8:13-20, 1988. Pearle, D.L., Calcium antagonist in acute myocardial infarction. American Journal of Cardiology 61:22B-25B, 1988. Satler, L.F., D.L., Pearle, and C.E. Rackley. Reduction in coronary heart disease: Anatomical considerations. Clinical Cardiology 12:422-426, 1989. Katz, N., P. Pierce, R. Anzeck, M. Visner, H. Canter, M. Forgh, D.L., Pearle, C.M. Tracy, and A. Rahman. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. The Journal of Heart Transplantation, 9:14-17, Jan/Feb, 1990. Pearle, D.L., Pharmacological management of ischemic heart disease with B-blockers and calcium channel blockers. American Heart Journal 120:739-742, September, 1990. Packer, M., Narahara K.A., Elkayam U., Sullivan J.M., D.L., Pearle, Massie, B.M., and Creager, M.A. Double blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Journal American College of Cardiology, 22(1):65-72, July, 1993. Coughlin, S.S., D.L., Pearle, K.L. Baughman, A. Wasserman, and M.C. Tefft, Diabetes mellitus and the risk of idiopathic dilated cardiomyopathy. Annals of Epidemiology, 4:45-52, 1994. Pearle, D.L. and DiBianco, R. Clinical Approach to Heart Failure in Classic Teachings in Teachings in Clinical Cardiology, Laennec Publishing, 1996. Antman EM., Anbe DT, Armstrong PW, Bates, ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial infarction-Executive Summary. J AM Coll Cardiol 2004,44: 671-719 Antman EM., Anbe DT, Armstrong PW, Bates, ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial infarction-Executive Summary. Circulation. 2004, 110:588-636 Antman EM, Hand M, Armstrong, PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CT, Pearle DL, Sloan MA, Smith SC, 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. J Am Coll Cardiology, 2008, 51:210 / j.jacc.2007.10.001 Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey JR, Bates ER, Blankenship JC, Casey DE, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson, ED, Sloan MA, Whitlow PL, Williams DO, 2009 Focused Updates : ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myuocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention. J. Am Coll Cardiol, 2009, 54 : 2005-224/j.jacc. 2009.10.015

Source: http://medstarhealthphysicians.org/documents/FAD/Pearle_David_Bio.pdf